Skip to main content

6 Result(s)

within Justine Yang Bruce Remove this filter Medicine & Public Health Remove this filter

and

  1. No Access

    Article

    Pharmacodynamic study using FLT PET/CT in advanced solid malignancies treated with a sequential combination of X-82 and docetaxel

    A sequential approach, synchronizing cell-cycle specific chemotherapy during VEGFR-TKI treatment breaks, may improve the therapeutic index of this combination therapy. In this study we investigate the safety/t...

    Matthew Scarpelli, Murtuza Rampurwala… in Cancer Chemotherapy and Pharmacology (2018)

  2. No Access

    Article

    18F-FLT PET/CT imaging in patients with advanced solid malignancies treated with axitinib on an intermittent dosing regimen

    This study utilizes FLT PET/CT imaging to characterize changes in tumor cell proliferation and vasculature during intermittent treatment with VEGR-TKI axitinib.

    Matthew Scarpelli, Justine Yang Bruce… in Cancer Chemotherapy and Pharmacology (2016)

  3. No Access

    Article

    A pharmacodynamically guided dose selection of PF-00337210 in a phase I study in patients with advanced solid tumors

    PF-00337210 is an oral, highly selective vascular endothelial growth factor receptor (VEGFR) inhibitor. We evaluated a composite of biomarkers in real time to identify the recommended phase 2 dose (RP2D) and p...

    Justine Yang Bruce, Patricia M. LoRusso… in Cancer Chemotherapy and Pharmacology (2016)

  4. No Access

    Article

    Pharmacodynamic study of axitinib in patients with advanced malignancies assessed with 18F-3′deoxy-3′fluoro-l-thymidine positron emission tomography/computed tomography

    Rapid disease progression associated with increased tumor proliferation has been observed during withdrawal of anti-angiogenic therapy. We characterize the dynamics of withdrawal flare for axitinib.

    Justine Yang Bruce, Peter Colin Scully… in Cancer Chemotherapy and Pharmacology (2015)

  5. No Access

    Article

    A phase I pharmacodynamic trial of sequential sunitinib with bevacizumab in patients with renal cell carcinoma and other advanced solid malignancies

    Sunitinib treatment results in a compensatory increase in plasma VEGF levels. Acute withdrawal of sunitinib results in a proliferative withdrawal flare, primarily due to elevated VEGF levels. Concurrent sunitini...

    Justine Yang Bruce, Jill M. Kolesar, Hans Hammers… in Cancer Chemotherapy and Pharmacology (2014)

  6. No Access

    Article

    A phase II study of 2-methoxyestradiol nanocrystal colloidal dispersion alone and in combination with sunitinib malate in patients with metastatic renal cell carcinoma progressing on sunitinib malate

    Background Current treatment for metastatic renal cell cancer with vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors (TKI) have provided improved overall survival, but complete...

    Justine Yang Bruce, Jens Eickhoff, Roberto Pili… in Investigational New Drugs (2012)